VIVUS, Inc. (NASDAQ:VVUS)

Home >> Stock >> VIVUS, Inc. >> Metrics

VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, and nonalcoholic steatohepatitis; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; Alvogen Malta Operations (ROW) Ltd; and Janssen Pharmaceuticals, Inc. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California....

+See More

Blog+More

U.S. senators urge the Trump administration to prevent the IMF from bailing out several countries that face predatory Chinese loans.

Chanel Holden

2018-02-01 07:38:00 Thursday ET

U.S. senators urge the Trump administration to prevent the IMF from bailing out several countries that face predatory Chinese loans.

U.S. senators urge the Trump administration with a bipartisan proposal to prevent the International Monetary Fund (IMF) from bailing out several countries t

+See More

Bidenomics better balances fiscal deficits and government expenditures with new corporate and capital income tax hikes.

Apple Boston

2021-08-01 07:26:00 Sunday ET

Bidenomics better balances fiscal deficits and government expenditures with new corporate and capital income tax hikes.

The Biden administration launches economic reforms in fiscal and monetary stimulus, global trade, finance, and technology. President Joe Biden proposes s

+See More

Agile business firms beat the odds by building faster institutional reflexes to anticipate plausible economic scenarios.

Fiona Sydney

2020-09-03 10:26:00 Thursday ET

Agile business firms beat the odds by building faster institutional reflexes to anticipate plausible economic scenarios.

Agile business firms beat the odds by building faster institutional reflexes to anticipate plausible economic scenarios. Christopher Worley, Thomas Willi

+See More

Is higher stock market concentration good or bad for Corporate America?

Laura Hermes

2025-03-03 04:11:06 Monday ET

Is higher stock market concentration good or bad for Corporate America?

Is higher stock market concentration good or bad for Corporate America? In recent years, S&P 500 stock market returns exhibit spectacular concentrati

+See More

Jared Diamond delves into how some societies fail, succeed, and revive in global human history.

Becky Berkman

2023-08-28 08:26:00 Monday ET

Jared Diamond delves into how some societies fail, succeed, and revive in global human history.

Jared Diamond delves into how some societies fail, succeed, and revive in global human history. Jared Diamond (2004)   Collapse: how societies

+See More

President Trump tweets that he asks the SEC to assess the practical implications of switching to a 6-month corporate disclosure cycle.

John Fourier

2018-08-17 11:45:00 Friday ET

President Trump tweets that he asks the SEC to assess the practical implications of switching to a 6-month corporate disclosure cycle.

In accordance with the extant corporate disclosure rules and requirements, all U.S. public corporations have to report their balance sheets, income statemen

+See More